stockrow
Saturday 7 November 2026
Export SGP’s income statement to Excel — free account
SpyGlass Pharma, Inc.
36.42
2.34
+6.87%
Follow SGP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (13) | (29) | (40) | (51) | +73.0% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | (13) | (29) | (40) | (56) | +73.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (7.66) | (16.31) | (17.98) | (9.05) | +53.2% | ||||||
| Cash flow | — | — | — | — | — | — | — | (7.06) | (12.32) | (14.75) | (1.30) | +44.5% | ||||||
| Capex | — | — | — | — | — | — | — | (0.12) | (1.11) | (0.36) | (0.08) | +69.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (7.19) | (13.43) | (15.11) | (1.39) | +45.0% | ||||||
| Book value | — | — | — | — | — | — | — | (18.98) | (33.82) | (44.58) | 6.95 | +53.3% | ||||||
| Shares, m | — | — | — | — | — | — | — | 2 | 2 | 2 | 5,548 | +12.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (12) | (22) | (33) | (44) | +63.2% | |||||
| Capex | — | — | — | — | — | — | — | 0 | (2) | (1) | (3) | +90.9% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (12) | (24) | (33) | (46) | +63.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 39 | 10 | 100 | 227 | +60.2% | |||||
| Net debt | — | — | — | — | — | — | — | (40) | (16) | (107) | (234) | +63.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (33) | (60) | (99) | 232 | +73.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (90.48) | (57.29) | (35.97) | (57.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 62.41 | 50.05 | (51.34) | +50.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 65 | 65 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
SpyGlass Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| SGP SpyGlass Pharma, Inc. | $1.1B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | |
| RAPP Rapport Therapeutics, Inc. | $1.1B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| SPTX Seaport Therapeutics, Inc | $1.1B | — (loss-making) | — | — | n/m | −43.81% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +113.59% | — | −43.81% | 0.00% | 0.00% |